CPE-215®
Permeation Enhancement
Technology

Permeation enhancement with CPE-215 is Bentley’s patented drug delivery technology. Bentley’s CPE-215 technology enhances the absorption of drugs across a variety of biological membranes, including the skin, mouth, nose and eye. Bentley is working to adapt the technology to products formulated as creams, ointments, gels, solutions, lotions, sprays or patches.

Bentley’s technology was validated in the product Testim and approved for marketing in the U.S. and numerous EU countries. Bentley determined that the technology could be extended beyond these applications to improve drug delivery of more complex molecules, especially therapeutic peptides for treatment of chronic diseases. Development work indicated that this technology employing the key excipient CPE-215 could be incorporated into Nasulin™, our patented product candidate for the intranasal administration of insulin. Nasulin is currently in Phase II global clinical trials.

We believe that key benefits of Bentley’s patented drug permeation technology using CPE-215 may include therapeutic and commercial advantages:

  • Improved compliance and convenience to diabetes patients requiring ongoing insulin administration
  • Earlier entry into prophylactic treatment for patients reluctant to administer insulin by injection
  • Reduction of long-term clinical sequelae and reduction of health-care costs by appropriate ongoing treatment
  • Application to other chronic injectable peptides to enable intranasal administration with similar benefits (clinical and economic)
  • Application to therapeutic molecules which are modified by passage through the liver and which benefit by elimination of first-pass metabolism by intra-nasal administration
  • Application to a variety of metabolic, neurological, and other serious medical conditions
  • Opportunities for life-cycle extension strategies for existing marketed products
  • Opportunities for allowing product differentiation based on benefits of administration
  • Enabling market entry to patients highly resistant to treatments employing injection, potentially children and the elderly